Funded Tech Companies
IsomAb
Wondering who backed IsomAb? MEIF Proof of Concept & Early Stage Fund, Broadview Ventures and Science Creates Ventures joined the equity holders in this life sciences company.
Company Overview
Company Name
IsomAb
Company Status
Private & Independent
Industry
Life Sciences
Funding Rounds
Total Funding
Contact Information
Mailing Address
Biocity Nottingham Innovation Building Pennyfoot Street
Nottingham, NG1 1GF
UK
Nottingham, NG1 1GF
UK
Phone
Undisclosed
Website
Email Address
Company Background Information
Overview
IsomAb is taking a different approach to identify, evaluate and develop isoform specific antibodies to treat disease where patients currently have limited or no treatment options. IsomAb is developing isoform specific antibodies and it has identified, using a combined bioinformatics/knowledge-based platform approach, ISM-001 which specifically inhibits the VEGF-A165b isoform of Vascular Endothelial Growth Factor-A (VEGF-A); based on 20 years of research by our two Founders, the evidence shows reducing serum levels of VEGF-A165b is key to ensuring new blood vessel formation in patients with ischemic disease.
Profile
Social Media
Company News
Facebook
YouTube
Last Transaction
2/20/2024
Financing History
Date
Type
Amount
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jackie Turnbull
Chief Financial Officer
Robin Pakenham
Chief Medical Officer
Stephen Harper
Chief Scientific Officer
David Bates
VP - Bus. Development
Chris Beattie
VP - Bus. Development
Kevin Brady
VP - Product Management
Kishor Modha
Company Investors
Browse more funded tech companies:
Share this article
About Our Venture Capital Database
This tech company profile is powered by VentureDeal.com, a leading supplier of venture capital funding data.
Additional Resources for Entrepreneurs